An early hint, then a firmer test.
The ETASS trial in 2013 studied 361 patients and hinted at fewer deaths with the drug.
The larger TESTS trial, published in BMJ in 2025, enrolled 1,106 patients and found no clear reduction in deaths.
StartStudy results
A promising headline can leave out the comparison that matters. Look for what happened to people, and what the study could not answer.
In 2024, the FDA review examined 12 possible uses of thymosin alpha-1 and found insufficient evidence for each.
The FDA is the U.S. drug review agency. Its finding does not prove the substance can never work.
Sepsis is a life-threatening response to an infection. These studies involved people being treated in hospitals.
Their results do not answer whether a healthy adult benefits from thymosin alpha-1.
The ETASS trial in 2013 studied 361 patients and hinted at fewer deaths with the drug.
The larger TESTS trial, published in BMJ in 2025, enrolled 1,106 patients and found no clear reduction in deaths.
The trial tracked deaths within 28 days.
The TESTS authors declared support from the drug’s maker, SciClone Pharmaceuticals.
In 2025, a journal review combined results from 11 trials of sepsis care.
Taken together, the trials suggested that fewer people died.
The reviewers also checked two smaller sets of trials. First, they kept only trials they rated higher quality, meaning they judged the results more trustworthy. That set did not show a clear benefit. Then they kept only trials run at several hospitals. That set did not show a clear benefit either. The apparent benefit depended on which trials were included.